Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2010 Jul 12;24(4):273–277. doi: 10.1002/jcla.20399

Ischemia‐Modified albumin levels in patients with end‐stage renal disease patients on hemodialysis: does albumin analysis method affect albumin‐adjusted Ischemia‐Modified albumin levels?

Aysel Kıyıcı 1,✉, İdris Mehmetoğlu 1, Hatice Karaoğlan 1, Hüseyin Atalay 2, Yalçın Solak 2, Süleyman Türk 2
PMCID: PMC6647578  PMID: 20626021

Abstract

Ischemia‐Modified albumin (IMA) has been used as an early marker in the evaluation of the patients with acute coronary syndrome. We aimed to evaluate IMA in end‐stage renal disease (ESRD) patients on hemodialysis and the effect of albumin methods on albumin‐adjusted IMA levels. A total of 30 ESRD patients were included in this study. Serum IMA and albumin levels were measured before and after a hemodialysis session. Albumin concentrations were determined with bromocresol green and bromocresol purple methods. Postdialysis IMA and albumin‐adjusted IMA levels with two different albumin methods were significantly increased compared with the predialysis levels (P<0.05). However, we did not find any difference in albumin‐adjusted IMA levels in either at the beginning or at the end of the dialysis session. IMA levels increase after hemodialysis, whereas albumin method has no effect on albumin‐adjusted IMA levels. J. Clin. Lab. Anal. 24:273–277, 2010. © 2010 Wiley‐Liss, Inc.

Keywords: Ischemia‐Modified albumin, Bromocresol green, Bromocresol purple, end stage renal disease, hemodialysis

REFERENCES

  • 1. Bar‐Or D, Lau E, Winkler JV. A novel assay for cobalt‐albumin binding and its potential as a marker for myocardial ischemia—A preliminary report. J Emer Med 2000;19:311–315. [DOI] [PubMed] [Google Scholar]
  • 2. Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischaemia and myocardial infarction. Clin Chem 2003;49:581–585. [DOI] [PubMed] [Google Scholar]
  • 3. Bar‐Or D, Lau E, Rao N, Bampos N, Winkler JV, Curtis CG. Reduction in the cobalt‐binding capacity of human albumin with myocardial ischaemia. Ann Emer Med 1999;34:S56. [Google Scholar]
  • 4. Peacock F, Morris DL, Anwaruddin S, et al. Meta‐analysis of ischemia‐modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253–262. [DOI] [PubMed] [Google Scholar]
  • 5. Troxler M, Thompson D, Homer‐Vanniasinkam S. Ischaemic skeletal muscle increases serum ischaemia modified albumin. Eur J Vasc Endovasc Surg 2006;31:164–169. [DOI] [PubMed] [Google Scholar]
  • 6. Abboud H, Labreuche J, Meseguer E, et al. Ischemia‐modified albumin in acute stroke. Cerebrovasc Dis 2007;23:216–220. [DOI] [PubMed] [Google Scholar]
  • 7. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia‐modified albumin in the diagnosis of pulmonary embolism. Am J Emer Med 2007;25:770–773. [DOI] [PubMed] [Google Scholar]
  • 8. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113–114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Şeneş M, Kazan N, Coşkun O, Zengi O, Inan L, Yücel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007;44:43–47. [DOI] [PubMed] [Google Scholar]
  • 10. Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010;95:586–591. Epub 2009 Dec 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010;43:450–454. [DOI] [PubMed] [Google Scholar]
  • 12. Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C‐reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi 2009;45:805–808. [PubMed] [Google Scholar]
  • 13. Wong CK, Szeto CC, Chan MH, Leung CB, Li PK, Lam CW. Elevation of pro‐inflammatory cytokines, C‐reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest 2007;36:47–57. [DOI] [PubMed] [Google Scholar]
  • 14. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129–2140. [DOI] [PubMed] [Google Scholar]
  • 15. Zapico‐Muniz E, Santalo‐Bel M, Merce‐Muntanola J, Montiel JA, Martinez‐Rubio A, Ordonez‐Llanos J. Ischemia‐modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063–1065. [DOI] [PubMed] [Google Scholar]
  • 16. van der Zee PM, Verberne HJ, van Straalen JP, et al. Limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischaemia. Clin Chem 2005;51:1744–1746. [DOI] [PubMed] [Google Scholar]
  • 17. Gaze DC, Crompton L, Collinson P. Ischaemia‐modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract 2006;15:322–324. [DOI] [PubMed] [Google Scholar]
  • 18. Lee YW, Kim HJ, Cho YH, Shin HB, Choi TY, Lee YK. Application of albumin‐adjusted ischaemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24–27. [DOI] [PubMed] [Google Scholar]
  • 19. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischaemia‐modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261–262. [DOI] [PubMed] [Google Scholar]
  • 20. Wells FE, Addison GM, Postiethwaite RJ. Albumin analysis in serum of haemodialysis patients: discrepancies between bromocresol purple, bromocresol green and electroimmunoassay. Ann Clin Biochem 1985;22:304–309. [DOI] [PubMed] [Google Scholar]
  • 21. Mabuchi H, Nakahashi II. Underestimation of serum albumin by the bromocresol purple method and a major endogenous ligand in uremia. Clin Chim Acta 1987;167:89–96. [DOI] [PubMed] [Google Scholar]
  • 22. Beyer C, Boekhout M, van Iperen H. Bromocresol purple dye‐binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure. Clin Chem 1994;40:844–845. [PubMed] [Google Scholar]
  • 23. Carfray A, Patel K, Whitaker P, Garrick P, Griffiths GJ, Warwick GL. Albumin as an outcome measure in haemodialysis in patients: The effect of variation in assay method. Nephrol Dial Transplant 2000;15:1819–1822. [DOI] [PubMed] [Google Scholar]
  • 24. Parikh C, Yalavarthy R, Gurevich A, Robinson A, Teitelbaum I. Discrepancies in serum albumin measurements vary by dialysis modality. Ren Fail 2003;25:787–796. PMID: 14575287. [DOI] [PubMed] [Google Scholar]
  • 25. Sharma R, Gaze DC, Pellerin D, et al. Ischemia‐modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493–502. [DOI] [PubMed] [Google Scholar]
  • 26. Sharma R, Gaze DC, Pellerin D, et al. Evaluation of ischaemia‐modified albumin as a marker of myocardial ischaemia in end‐stage renal disease. Clin Sci 2007;113:25–32. [DOI] [PubMed] [Google Scholar]
  • 27. Cichota LC, Moresco RN, Duarte MMF, da Silva JEP. Evaluation of ischemia‐modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008;22:1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Carrega L, Giaime P, Montserrat C, et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006;54:62–66. [DOI] [PubMed] [Google Scholar]
  • 29. Malindretos P, Sarafidis PA, Rudenco I, et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol 2007;27:572–579. [DOI] [PubMed] [Google Scholar]
  • 30. Montagnana M, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 2008;22:59–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Lowrie EG, Lew NL. Death risk in haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482. [DOI] [PubMed] [Google Scholar]
  • 32. Turley CP, Andries LA, Arnold WA. Dye binding and electrophoretic techniques compared for albumin assay in hypoalbumenic sera. Clin Chem 1985;31:336–337. [PubMed] [Google Scholar]
  • 33. Leerunck CB, Winckers EKA. Multilayer‐film bromocresol green method for albumin measurement significantly inaccurate when albumin/globulin ratio is <0.8[Letter]. Clin Chem 1991;37:766–767. [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES